Member Info for Krone

Hi PCS,

Yes, at this stage of the game it’s surely reasonable to expect forensic level of attention to detail, not the introduction of further uncertainty.

GLA

Sale of SRA737 will address the funding issue in one fell swoop!

Would have thought that this warrants more than the briefest of tweets….

https://x.com/sparksinsurrey/status/2069045624914301281?s=46&t=_cUs6qcowyQbbF4MoPYSCw

Who knows, if the long awaited SRA737 flip turns out to be something very substantial this will undoubtedly strengthen SP’s/Sareum’s negotiating position in respect of SDC1801, 2 and 3 placing is in the realms of possible billion or multi billions territory. Could be a very hot week on all fronts!!

Good luck all.

Https://pharmaphorum.com/news/biogen-pens-1bn-deal-buy-immunology-biotech-raythera

Hi HBD,

Thanks yes, I appreciate that we’re targeting Jak1….it was more the deal size that caught my eye.

All the best.

Https://www.fiercebiotech.com/biotech/lilly-23b-ajax-deal-first-clinical-data-jak-inhibitor-works-right-out-gate?utm_medium=email&utm_source=nl&utm_campaign=LS-NL-FierceBiotech&oly_enc_id=8331F3744801G2C

It will be interesting to see if anything SRA737 related emerges from the ASCO conference…..

Perhaps the Chairman’s update will kick start some momentum so the SP gets closer to the temperature…..

Https://www.fiercebiotech.com/biotech/lilly-continues-ma-streak-23b-deal-next-gen-jak-inhibitor-biotech-ajax

In this real-world study, deucravacitinib showed significant and sustained effectiveness, together with a favorable safety profile, in patients with moderate-to-severe plaque psoriasis. These findings support its role as an effective oral targeted therapy in routine clinical practice.

https://academic.oup.com/ced/advance-article-abstract/doi/10.1093/ced/llag187/8662642?redirectedFrom=fulltext&utm_source=chatgpt.com

Thanks Potnak, sleuthing at its best!

Particularly enticing “ The primary researcher behind the breakthrough showing SRA737’s immune-remodeling capability.”

ATB

Https://www.businessweekly.co.uk/posts/sareum-continues-fightback-in-six-months-to-end-december?lh_aid=28468&lh_cid=czv7w8u4x2&lh_em=info%40amundsen.co.uk&di=09b37b9f3c0e7da08155cc085206e6ce

Good morning C79,

Excellent finds as always!

The dot joining will surely end up with a masterpiece…or is that painting by numbers…you get the gist!

Thanks so much.

ATVB

Notice of Allowance received from US Patent and Trademark Office for an application protecting the crystal form of SRA737 drug substance, extending patent protection until at least April 2041.

Given that SRA737 is likely to be the most significant near term catalyst to get the SP moving, it would be encouraging to get some hint of how/if negotiations are proceeding, albeit with the constraints of the RNS rules.

Do any other long term investors start to get the feelings of quiet anticipation on a Sunday evening which by Monday morning have turned into mildly adrenaline fuelled naive expectations that this week may just be different, from the many hundreds of previous weeks, and there may be some substantive news…..only to get to Friday once again with nothing and the accompanying sinking stomach feeling. God knows we all deserve a medal for patience!

Https://qtx.omeclk.com/portal/wts/ue%5EcmQ6kmV2bc-n%5BaR%5E%5E66srkEnv2jrcOP7v-sPdOa

Clearly Dr Parker is listening to investors!

https://x.com/sparksinsurrey/status/2014280979293036549?s=46&t=_cUs6qcowyQbbF4MoPYSCw

Good morning C79 and many thanks as always for your post.

The weight of evidence supporting the progression of SRA737 is substantial and it would astonishing if we don’t hear something positive soon!

ATVB